Table 1.
PFS and OS in maintenance and TFI trials.
| Post-IT strategy | Strategy | Trials | Phase | N | IT duration (months) |
mPFS | PFS | mOS | OS | Trial result |
|---|---|---|---|---|---|---|---|---|---|---|
| Complete stop | TFI after chemo alone | COIN [Adams et al. 2011] | III | 815 | 3 | - | - | - | 14.4 | TFI < continuous |
| OPTIMOX2 [Chibaudel et al. 2009] | IIR | 104 | 3 | - | 6.6 | - | 19.5 | TFI < FU | ||
| TFI after chemo-bev | CAIRO3 [Koopman et al. 2013] | III | 279 | 4.5 | 4.1 | - | 18.2 | - | TFI < bev/FU | |
| AIO KRK 0207 [Arnold et al. 2014] | III | 158 | 6 | 3.6 | - | 23.3 | - | TFI < bev = bev/FU | ||
| SAKK 41/06 [Koeberle et al. 2013] | III | 123 | 4-6 | 3.1* | 8.5 | - | 22.8 | TFI < bev | ||
| TFI after chemo-cetux** | COIN-B [Wasan et al. 2014] | IIR | 64 | 3 | 3.1 | - | - | 16.8 | TFI < cetux | |
| Maint. 1 agent | FU maint. after chemo alone | OPTIMOX1 [Tournigand et al. 2006] | III | 309 | 3 | - | 8.7 | - | 21.2 | FU = continuous |
| OPTIMOX2 [Chibaudel et al. 2009] | IIR | 98 | 3 | - | 8.6 | - | 23.8 | FU > TFI | ||
| Bev maint. after chemo-bev | TTD MACRO [Diaz-Rubioet al. 2012] | III | 241 | 4.5 | - | 9.7 | - | 20.0 | bev = continuous | |
| AIO KRK 0207 [Arnold et al. 2014] | III | 156 | 6 | 4.6 | - | 22.6 | - | Bev > TFI | ||
| SAKK 41/06 [Koeberle et al. 2013] | III | 124 | 4-6 | 4.5* | 9.5 | - | 24.9 | Bev > TFI | ||
| DREAM [Chibaudel et al. 2014b] | III | 228 | 3-6 | 4.9 | 9.3 | 22.1 | 27.0 | Bev < bev/erlo | ||
| ACT-1 [Johnsson et al. 2013] | III | 79 | 4.5 | 4.2 | - | 22.8 | - | bev = bev/erlo | ||
| Cetux maint. after chemo-cetux** | NORDIC VII [Tveit et al. 2012]MACRO-2 [Alfonso et al. 2014] | IIIIIR | 109129 | 44 | − | 7.58.9 | − | 21.423.6 | cetux = continuouscetux < continuous | |
| COIN-B [Wasan et al. 2014] | IIR | 66 | 3 | 5.8 | - | - | 22.2 | cetux > TFI | ||
| Maint. 2 agents | Bev/FU maint after chemo-bev | CAIRO3 [Koopman et al. 2013]AIO KRK 0207 [Arnold et al. 2014] | IIIIII | 279158 | 4.56 | 8.56.2 | − | 21.723.4 | − | bev/FU > TFIbev/FU = bev |
| Bev/erlotinibmaint. after chemo-bev | DREAM [Chibaudel et al. 2014b]ACT-1 [Johnsson et al. 2013] | IIIIII | 224 80 | 3-64.5 | 5.95.7 | 10.0- | 24.921.5 | 30.0- | bev/erlo > bevbev/erlo = bev |
*
TTP; **KRAS wild-type population
Abbreviations: TTP, time to progression; PFS, progression-free survival; OS, overall survival; TFI, treatment-free interval; IT, induction therapy; m, median; chemo, chemotherapy; bev, bevacizumab; cetux, cetuximab; FU, fluoropyrimidine; erlo, erlotinib; maint., maintenance.